Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PRLX 93936

Next Previous
X
Search
Drug Profile

PRLX 93936

Alternative Names: Erastin analogue; PRLX 82845; PRLX93936

Latest Information Update: 22 Sep 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Columbia University; Whitehead Institute for Biomedical Research
  • Developer Prolexys Pharmaceuticals
  • Class Quinazolinones; Small molecules
  • Mechanism of Action Ion channel modulators; Ras protein inhibitors; Signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Multiple myeloma; Solid tumours

Most Recent Events

  • 01 Mar 2012 Phase-I/II clinical trials in Multiple myeloma (Second-line therapy) in USA (IV)
  • 01 Nov 2011 Prolexys completes a phase I trial in Advanced solid tumours in USA (NCT00528047)
  • 10 Feb 2011 Prolexys completes enrolment in its Phase I trial in Solid tumours in USA (NCT00528047)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top